pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,579 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
    A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching ​an agreement allowing Teva to market a generic ‌version of Forteo
    STAT · 11d ago↗ source
  • Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better
    LONDON — Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet that it could slow dementia. But the results wer…
    Endpoints · 11d ago↗ source
  • STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
    An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.
← prev
page 11 of 64
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 11d ago
↗ source
  • Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
    <figure><div><img src="https://imgproxy.divecdn.com/Bdi5M4HMTn0nQ7Ww6DWMZBEaPY1McVmIyhbOSlOBYfo/g:nowe:0:194/c:1920:1085/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS8zODY4NjUwMzI1M…
    BioPharma Dive · 11d ago↗ source
  • Draig nets $65M to advance depression drug aimed at rebuilding synapses
    Draig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…
    Endpoints · 11d ago↗ source
  • Genetic medicine startup Lyora launches with programs from Editas, Biogen
    Lyora Therapeutics will try to revive several early-stage genetic eye disease programs previously held by Editas Medicine and Biogen. The biotech was co-founded by Luk Vandenberghe and Eric Pie…
    Endpoints · 11d ago↗ source
  • AstraZeneca to take rights to Dizal's lung cancer pill Zegfrovy
    AstraZeneca is set to pay Dizal Pharmaceutical, which it part-owns, $600 million upfront for worldwide development and sales rights to the lung cancer drug Zegfrovy. The UK pharma said Tuesday th…
    Endpoints · 11d ago↗ source
  • In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic
    After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet. An autoimmune drug candidate from…
    Endpoints · 11d ago↗ source
  • Former Akero team announces new I&I company, Avere, with China drug
    Everything around China biotech really does seem to be speeding up. On Tuesday, the former executive team behind Akero Therapeutics unveiled a new company, a pipeline drug from China and a revers…
    Endpoints · 11d ago↗ source
  • FDA authorized Zyn nicotine pouches without knowing what they were made of, says former agency scientist
    A former FDA toxicologist has accused the agency of authorizing Zyn nicotine pouches without fully reviewing their safety
    STAT · 11d ago↗ source
  • Opinion: It looks like your doctor and talks like your doctor. But it’s not your doctor
    Deepfakes undermine the credibility that makes digital care — from telehealth visits to patient portals — possible.
    STAT · 11d ago↗ source
  • STAT+: 10 charts that explain America’s hidden alcohol epidemic
    America's hidden alcohol epidemic — the toll, emerging risks, shifting usage, and economic stakes — broken down in 10 charts.
    STAT · 11d ago↗ source
  • 12 ideas for tackling the U.S. alcohol epidemic
    The U.S. can save lives from excess alcohol use without taking drastic measures. Here are 12 steps that can help.
    STAT · 11d ago↗ source
  • STAT+: Drug metabolism AI competition results show that bigger may not always be better
    The results of a recent AI competition show that better data trumps bigger models when it comes to predicting properties of drug candidates.
    STAT · 11d ago↗ source
  • STAT+: AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents
    A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention.
    STAT · 11d ago↗ source
  • Cayman court says Apple Tree general partner should lose control of venture fund
    The embattled venture firm Apple Tree Partners has suffered a loss in a Cayman Islands court case against its main limited partner. A judge in the Grand Court of the Cayman Islands ruled on Frida…
    Endpoints · 12d ago↗ source
  • FDA finalizes guidance on psychedelics, plans broader hearing
    The FDA has finalized clinical guidance for psychedelic drug developers and has scheduled a public hearing on future therapeutic use, adding regulatory momentum to a class on the precipice of appro…
    Endpoints · 12d ago↗ source
  • Freenome colorectal cancer test data improve on earlier results
    <figure><div><img src="https://imgproxy.divecdn.com/t2eSQFnULTRPQ6pHoF74ilRTdrAlEvvFROsITsihAlw/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDUzMDQ1NTczLmpwZ…
    BioPharma Dive · 12d ago↗ source
  • FDA proposes rule to simplify drugmakers' factory registrations
    The FDA is proposing a rule to change how factories are registered with the agency if they are making products for the US market, as part of a continuing effort to try to speed up ...
    Endpoints · 12d ago↗ source
  • STAT+: Dementia study replicates promising outcomes following risk-reduction strategies
    A dementia prevention trial praised as a "landmark" effort further demonstrated the promise of structured programs tailored to local cultures.
    STAT · 12d ago↗ source
  • Q32 bounces back to claim study success for alopecia drug
    <figure><div><img src="https://imgproxy.divecdn.com/_dT9zKJsCoS0jrFraV8Vdkcut5aCVtKPN0y1PuLlKnE/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTUwMzE2NTA1LmpwZ…
    BioPharma Dive · 12d ago↗ source
  • Health tech funding rises to $7.4B in the first half of 2026
    Digital health startups raised $7.4 billion in venture funding during the first half of 2026, up $1 billion from the first half of 2025, according to research and venture firm Rock Health. Megaro…
    Endpoints · 12d ago↗ source
  • Agenus surges on study pivot; Apnimed lines up an IPO
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 12d ago↗ source
  • STAT+: UnitedHealth’s questionable review, and more MA stars lawsuits
    UnitedHealth touts a new home care audit, and more health insurers sue CMS over Medicare Advantage quality ratings.
    STAT · 12d ago↗ source
  • Busy M&A activity sets tone as biopharma earnings season kicks off
    With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the biopharma industry: Will the good times continue? The answer to that…
    Endpoints · 12d ago↗ source